Davis's Drug Guide
necitumumab
General
Genetic Implications:
Pronunciation:
ne-si-toom-oo-mab
To hear audio pronunciation of this topic, purchase a subscription or log in.Trade Name(s)
- Portrazza
Ther. Class.
Pharm. Class.
epidermal growth factor receptor (EGFR) inhibitors
monoclonal antibodies
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Vallerand, April Hazard., et al. "Necitumumab." Davis's Drug Guide, 18th ed., F.A. Davis Company, 2023. www.drugguide.com/ddo/view/Davis-Drug-Guide/110400/all/necitumumab.
Vallerand AHA, Sanoski CAC, Quiring CC. Necitumumab. Davis's Drug Guide. F.A. Davis Company; 2023. https://www.drugguide.com/ddo/view/Davis-Drug-Guide/110400/all/necitumumab. Accessed June 4, 2023.
Vallerand, A. H., Sanoski, C. A., & Quiring, C. (2023). Necitumumab. In Davis's Drug Guide (18th ed.). F.A. Davis Company. https://www.drugguide.com/ddo/view/Davis-Drug-Guide/110400/all/necitumumab
Vallerand AHA, Sanoski CAC, Quiring CC. Necitumumab [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2023. [cited 2023 June 04]. Available from: https://www.drugguide.com/ddo/view/Davis-Drug-Guide/110400/all/necitumumab.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - necitumumab
ID - 110400
A1 - Sanoski,Cynthia A,
AU - Vallerand,April Hazard,
AU - Quiring,Courtney,
BT - Davis's Drug Guide
UR - https://www.drugguide.com/ddo/view/Davis-Drug-Guide/110400/all/necitumumab
PB - F.A. Davis Company
ET - 18
DB - Davis's Drug Guide
DP - Unbound Medicine
ER -